Claims for Patent: 11,484,535

Summary for Patent: 11,484,535

Title:	Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a] pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
Abstract:	A liquid formulation of (S)—N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide, pharmaceutically acceptable salts thereof, or a combination thereof and the use of the liquid formulation in the treatment of pain, cancer, inflammation, and certain infectious diseases are disclosed.
Inventor(s):	Mark Reynolds, Steven A Smith
Assignee:	Loxo Oncology Inc
Application Number:	US16/859,275
Patent Claims:	1. A method for treating a cancer in a subject in need thereof, wherein the cancer is mediated by a Trk kinase, the method comprising administering to the subject a therapeutically effective amount of a liquid formulation comprising: (S)—N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide having the formula (I): a pharmaceutically acceptable salt thereof, or a combination thereof; hydroxypropyl-β-cyclodextrin; sodium citrate; and a sweetener; wherein: the formulation has a pH of about 2.5 to about 5.5; and the compound of formula (I), the pharmaceutically acceptable salt thereof, or the combination thereof has a concentration of about 20 mg/mL to about 30 mg/mL in the liquid formulation. 2. The method of claim 1, wherein the subject is a human. 3. The method of claim 2, wherein the cancer is associated with one or more of overexpression, activation, amplification, and mutation of a Trk kinase. 4. The method of claim 2, wherein the cancer is determined to have a dysregulation of a NTRK gene, a Trk protein, or expression or activity or level of the same. 5. The method of claim 4, wherein the dysregulation of a NTRK gene, a Trk protein, or expression or activity or level of the same is a chromosome translocation that results in the translation of a Trk fusion protein. 6. The method of claim 5, wherein the Trk fusion protein is selected from the group consisting of: TP53-TrkA, LMNA-TrkA, CD74-TrkA, TFG-TrkA, TPM3-TrkA, NFASC-TrkA, BCAN-TrkA, MPRIP-TrkA, TPR-TrkA, RFWD2-TrkA, IRF2BP2-TrkA, SQSTM1-TrkA, SSBP2-TrkA, RABGAP1L-TrkA, C18ORF8-TrkA, RNF213-TrkA, TBC1D22A-TrkA, C20ORF112-TrkA, DNER-TrkA, ARHGEF2-TrkA, CHTOP-TrkA, PPL-TrkA, PLEKHA6-TrkA, PEAR1-TrkA, MRPL24-TrkA, MDM4-TrkA, LRRC71-TrkA, GRIPAP1-TrkA, EPS15-TrkA, DYNC2H1-TrkA, CEL-TrkA, EPHB2-TrkA, TGF-TrkA, NACC2-TrkB, QKI-TrkB, AFAP1-TrkB, PAN3-TrkB, SQSTM1-TrkB, TRIM24-TrkB, VCL-TrkB, AGBL4-TrkB, DAB2IP-TrkB, ETV6-TrkC, BTBD1-TrkC, LYN-TrkC, RBPMS-TrkC, EML4-TrkC, HOMER2-TrkC, TFG-TrkC, FAT1-TrkC, and TEL-TrkC. 7. The method of claim 4, wherein the dysregulation of a NTRK gene, a Trk protein, or expression or activity or level of the same is one or more point mutations in the gene. 8. The method of claim 7, wherein the one or more point mutations in the NTRK gene results in the translation of a TrkA protein having one or more of the following amino acid substitutions: R33W, A336E, A337T, R324Q, R324W, V420M, R444Q, R444W, G517R, G517V, K538A, R649W, R649L, R682S, V683G, R702C, or C1879T; the translation of a TrkB protein having one or more of the following amino acid substitutions: A13T, E142K, R136H, V619M, F663L, G639R, G709C, G709A, or G709S; or the translation of TrkC protein having one or more of the following amino acid substitutions: V603M, F617L, G623R, G696C, G696A, or G696S. 9. The method of claim 2, wherein hydroxypropyl-β-cyclodextrin is present in the liquid formulation in an amount of about 13 wt. % to about 17 wt. %. 10. The method of claim 9, wherein hydroxypropyl-β-cyclodextrin is present in the liquid formulation in an amount of about 15 wt. %. 11. The method of claim 2, wherein sodium citrate comprises at least one of sodium citrate monohydrate and sodium citrate dihydrate. 12. The method of claim 11, wherein sodium citrate comprises sodium citrate dihydrate. 13. The method of claim 12, wherein sodium citrate dihydrate is present in the liquid formulation in an amount of about 0.7 wt. % to about 1.5 wt. %. 14. The method of claim 13, wherein sodium citrate dihydrate is present in the liquid formulation in an amount of about 1.1 wt. %. 15. The method of claim 2, wherein the sweetener includes sucrose, glycerin, sorbitol, and flavoring. 16. The method of claim 15, wherein the sweetener further includes citric acid and sodium phosphate. 17. The method of claim 16, wherein the sweetener further includes methylparaben and potassium sorbate. 18. The method of claim 17, wherein the sweetener is present in the liquid formulation in an amount of about 45 wt. % to about 55 wt. %. 19. The method of claim 18, wherein the sweetener is present in the liquid formulation in an amount of about 50 wt. %. 20. The method of claim 2, wherein the liquid formulation further comprises a bitterness masking agent. 21. The method of claim 20, wherein the bitterness masking agent is present in the liquid formulation in an amount of about 0.2 wt. % to about 0.5 wt. %. 22. The method of claim 2, wherein the sweetener includes sucralose. 23. The method of claim 22, wherein the liquid formulation further comprises a flavoring agent. 24. The method of claim 23, wherein the flavoring agent is present in the liquid formulation in an amount of about 0.01 wt. % to about 0.1 wt. %. 25. The method of claim 2, wherein the liquid formulation has been prepared from a pharmaceutically acceptable salt of the compound of formula (I). 26. The method of claim 25, wherein the liquid formulation has been prepared from the hydrogen sulfate salt of the compound of formula (I). 27. The method of claim 2, wherein the liquid formulation comprises: (S)—N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide having the formula (I): a pharmaceutically acceptable salt thereof, or a combination thereof; hydroxypropyl-β-cyclodextrin present in an amount from about 13 wt. % to about 17 wt. %; sodium citrate dihydrate present in an amount from about 0.7 wt. % to about 1.5 wt. %; a sweetener that includes sucrose, glycerin, sorbitol, and flavoring, wherein the sweetener is buffered with citric acid and sodium phosphate, wherein the sweetener is preserved with methylparaben and potassium sorbate, and wherein the sweetener is present in an amount from about 45 wt. % to about 55 wt. %; and a bitterness masking agent present in an amount from about 0.2 wt. % to about 0.5 wt. %. 28. The method of claim 27, wherein hydroxypropyl-β-cyclodextrin is present in the liquid formulation in an amount of about 15 wt. %. 29. The method of claim 28, wherein sodium citrate dihydrate is present in the liquid formulation in an amount of about 1.1 wt. %. 30. The method of claim 29, wherein the bitterness masking agent is present in the liquid formulation in an amount of about 0.4 wt. %. 31. The method of claim 2, wherein the liquid formulation comprises: (S)—N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide having the formula (I): a pharmaceutically acceptable salt thereof, or a combination thereof; hydroxypropyl-β-cyclodextrin present in an amount from about 13 wt. % to about 17 wt. %; sodium citrate dihydrate present in an amount from about 0.7 wt. % to about 1.5 wt. %; a sweetener that includes sucralose; and a flavoring agent present in an amount from about 0.01 wt. % to about 0.1 wt. %. 32. The method of claim 31, wherein hydroxypropyl-β-cyclodextrin is present in the liquid formulation in an amount of about 15 wt. %. 33. The method of claim 32, wherein sodium citrate dihydrate is present in an amount of about 1.1 wt. %.